| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 145, 1191-1198, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
H Joensuu, L Pylkkanen and S Toikkanen
Department of Oncology, Turku University Central Hospital, Finland.
Bcl-2 gene product functions to prevent apoptosis in a variety of in vitro and in vivo experiments. The prognostic significance of Bcl-2 protein expression was investigated by immunocytochemistry from paraffin-embedded tissue in a series of 174 women with breast cancer, treated with radical surgery with or without regional radiotherapy, and who had been followed up for the median of 31 years or until death. A minority (25%) of cancers were entirely negative for Bcl-2 protein. Moderate to strong Bcl-2 protein expression (present in 46%) was strongly associated with several favorable prognostic features, such as a low mitotic count, high histological grade of differentiation, and lack of p53 protein expression (P < 0.0001 for each). It was also significantly associated with lack of tumor necrosis, a low S-phase fraction size, low cathepsin D expression, DNA diploidy, and the lobular histological type, but not with the primary tumor size or the axillary nodal status. Women with cancer with moderate to strong Bcl-2 protein expression had more favorable short-term (69% versus 46% alive at 5 years) but similar long-term (29% versus 33% alive at 30 years) disease-specific survival as those with cancer with weak or lacking expression. Bcl-2 protein expression did not have independent prognostic value in a multivariate survival analysis. We conclude that Bcl-2 protein is frequently expressed in breast cancer, and its expression is associated with favorable clinicopathological features.
This article has been cited by other articles:
 |
|
 |
|
  D Trere, L Montanaro, C Ceccarelli, S Barbieri, G Cavrini, D Santini, M Taffurelli, and M Derenzini Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast Ann. Onc., June 1, 2007; 18(6): 1004 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dai, D. Chen, R. A. Jones, L. H. Hurley, and D. Yang NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region Nucleic Acids Res., October 6, 2006; 34(18): 5133 - 5144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Ann. Onc., October 1, 2006; 17(10): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nahta, L. X.H. Yuan, D. J. Fiterman, L. Zhang, W. F. Symmans, N. T. Ueno, and F. J. Esteva B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1593 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ohkia, Y. Hu, M. Wang, F. U. Garcia, and M. E. Stearns Evidence for Prostate Cancer-Associated Diagnostic Marker-1: Immunohistochemistry and in Situ Hybridization Studies Clin. Cancer Res., April 1, 2004; 10(7): 2452 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. El-Bayoumy, B. A. Narayanan, D. H. Desai, N. K. Narayanan, B. Pittman, S. G. Amin, J. Schwartz, and D. W. Nixon Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray Carcinogenesis, September 1, 2003; 24(9): 1505 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gradilone, P. Gazzaniga, D. Ribuffo, S. Scarpa, E. Cigna, F. Vasaturo, U. Bottoni, D. Innocenzi, S. Calvieri, N. Scuderi, et al. Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients J. Clin. Oncol., January 15, 2003; 21(2): 306 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Giordano, A. U. Buzdar, and G. N. Hortobagyi Breast Cancer in Men Ann Intern Med, October 15, 2002; 137(8): 678 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hensel, A. Schneeweiss, H.-P. Sinn, G. Egerer, M. Kornacker, E. Solomayer, R. Haas, G. Bastert, and A. D. Ho Stem Cell Dose and Tumorbiologic Parameters as Prognostic Markers for Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy with Autologous Blood Stem Cell Support Stem Cells, January 1, 2002; 20(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax Expression in Invasive and in Situ Squamous Cell Carcinoma of the Uterine Cervix Clin. Cancer Res., September 1, 2000; 6(9): 3600 - 3606. [Abstract] [Full Text]
|
|
|
|
|
|
A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli, G. Gorzegno, B. DiMarco, S. Aguggini, G. Bolsi, F. Cirillo, et al. p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients Clin. Cancer Res., July 1, 2000; 6(7): 2751 - 2758. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Konopleva, A. M. Tari, Z. Estrov, D. Harris, Z. Xie, S. Zhao, G. Lopez-Berestein, and M. Andreeff Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood, June 15, 2000; 95(12): 3929 - 3938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa Expression of survivin and Its Relationship to Loss of Apoptosis in Breast Carcinomas Clin. Cancer Res., January 1, 2000; 6(1): 127 - 134. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. d. L. Coste, A. Mignon, M. Fabre, E. Gilbert, A. Porteu, T. V. Dyke, A. Kahn, and C. Perret Paradoxical Inhibition of c-myc-induced Carcinogenesis by Bcl-2 in Transgenic Mice Cancer Res., October 1, 1999; 59(19): 5017 - 5022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Sinicrope, J. Hart, H.-A. Hsu, M. Lemoine, F. Michelassi, and L. C. Stephens Apoptotic and Mitotic Indices Predict Survival Rates in Lymph Node-negative Colon Carcinomas Clin. Cancer Res., July 1, 1999; 5(7): 1793 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vakkala, K. Lahteenmaki, H. Raunio, P. Paakko, and Y. Soini Apoptosis during Breast Carcinoma Progression Clin. Cancer Res., February 1, 1999; 5(2): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Soini, P. Paakko, and V-P. Lehto Histopathological Evaluation of Apoptosis in Cancer Am. J. Pathol., October 1, 1998; 153(4): 1041 - 1053. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eissa and L. S. Seada Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry Clin. Chem., July 1, 1998; 44(7): 1423 - 1429. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
